-
公开(公告)号：US11478473B2
公开(公告)日：2022-10-25
申请号：US16839889
申请日：2020-04-03
发明人： Kazunori Goto , Jun Nakahigashi , Atsuya Sato , Yosuke Hirayama , Moeri Horikoshi , Noriyuki Kouda , Syoichiro Inoue , Ikutaro Sato , Manami Kato
IPC分类号： A61K31/4985 , A61P25/20 , A61P25/22
摘要： The present invention provides a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.
-
12.发明申请公开(公告)号：US20220277206A1
公开(公告)日：2022-09-01
申请号：US17619934
申请日：2020-06-17
摘要： Methods, systems, and computer programs for predicting an entity's adherence or non-adherence to a regimen. A method includes accessing observed attributes of an entity during a first time duration, accessing historical data describing attributes of another entity, where the historical data was previously obtained during respective second time durations, for each of the other entities, that are each equal in duration to the first time duration, filtering the historical data to only include historical data describing attributes of at least one other entity that satisfy a similarity threshold, the similarity threshold defining a relationship between the observed attributes and the historical data based on a distorted distance measure, collapsing the remaining historical data into one or more representative data, and for each representative data series, generating a similarity based prediction related to an outcome for the entity based on (i) the observed data and (ii) the representative data attributes.
-
公开(公告)号：US20220265557A1
公开(公告)日：2022-08-25
申请号：US17677726
申请日：2022-02-22
发明人： Syed Asfar Mateen , Praveen Kumar Mididoddi , Shailly Mehrotra , Susan Elizabeth Shoaf , Salin Gupta , Kai Suzuki , Masahiro Hasegawa
IPC分类号： A61K9/16 , A61K31/403
摘要： Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.
-
公开(公告)号：US20220202684A1
公开(公告)日：2022-06-30
申请号：US17606252
申请日：2020-04-24
发明人： Miyoko OGIHARA , Momoko SUMA , Shiori MIYAWAKI
摘要： The present disclosure provides an O/W emulsion composition, comprising an adenosine phosphate and/or a salt thereof; an acrylic acid-alkyl methacrylate copolymer; an oil content; and water; and comprising a water-soluble polymer selected from a swelling thickener, an associative thickener, a polysaccharide and a derivative thereof and a mixture thereof, and/or a pH adjuster which is an organic alkali compound; wherein the composition has a viscosity of less than 10,000 mPa·s.
-
公开(公告)号：US20220169638A1
公开(公告)日：2022-06-02
申请号：US17464166
申请日：2021-09-01
发明人： Michael READER , Nicola Elizabeth WILSHER , Mark Henry SAUNDERS , Paul Anthony BAGULEY , Colin Thomas LINDLEY , Robert Craig MELLING , Bozena Ewa ADAMCZYK , Mirka SCARATI
摘要： This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
-
公开(公告)号：US20220167607A1
公开(公告)日：2022-06-02
申请号：US17442396
申请日：2020-04-15
发明人： MIKHAIL ZOLOTUKHIN
IPC分类号： A01M21/04
摘要： The present invention is directed to a needle retention assembly, an injectate delivery system, a needle, and a safety mechanism, all of which are for use with an injection device. The needle retention assembly includes a needle offset nut which is configured to removably attach to a needle retention nut and to provide support to the needle. The injectate delivery system includes an injectate holding compartment, a plunger, and a resilient member. The needle has a sidewall defining a longitudinal channel and includes at least two orifices in the sidewall, but does not include an orifice at a tip of the needle. The safety mechanism includes a dual switch that includes two switch elements that are each positioned on opposing sides of a handle of the injection device.
-
公开(公告)号：US20220160621A1
公开(公告)日：2022-05-26
申请号：US17594292
申请日：2021-04-01
发明人： Matthew Harlin , Xiaofeng WANG , Yanlin WANG , Arash RAOUFINIA
IPC分类号： A61K9/00 , A61K31/496
摘要： The present disclosure is directed to the methods of treating a patient with schizophrenia or bipolar I disorder by administering to the patient an injectable preparation of aripiprazole, wherein the patient is administered the injectable preparation about once every two months.
-
公开(公告)号：US20220152064A1
公开(公告)日：2022-05-19
申请号：US17439061
申请日：2020-03-27
发明人： Tomihiko CHIHARA , Shingo UNO
IPC分类号： A61K31/675
摘要： A means for reducing side effects of tolvaptan is provided. Specifically, the means provides a pharmaceutical composition comprising a compound represented by Formula (1): or a metal salt thereof, wherein the pharmaceutical composition is used such that the compound represented by Formula (1) or a metal salt thereof is transvascularly administered in an amount of 4 to 20 mg over a period of 10 minutes or more.
-
公开(公告)号：US20220096638A1
公开(公告)日：2022-03-31
申请号：US17444469
申请日：2021-08-04
发明人： Daiki KANEKO , Takakuni MATSUDA , Yusuke HOSHIKA
摘要： An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s−1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s−1, as measured.
-
20.发明申请公开(公告)号：US20220054482A1
公开(公告)日：2022-02-24
申请号：US17459221
申请日：2021-09-09
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
-
-
-
-
-
-
-
-
搜索结果
523 条记录 (耗时 0.031 秒)